JP5593342B2 - ドセタキセルの製造方法 - Google Patents
ドセタキセルの製造方法 Download PDFInfo
- Publication number
- JP5593342B2 JP5593342B2 JP2012045438A JP2012045438A JP5593342B2 JP 5593342 B2 JP5593342 B2 JP 5593342B2 JP 2012045438 A JP2012045438 A JP 2012045438A JP 2012045438 A JP2012045438 A JP 2012045438A JP 5593342 B2 JP5593342 B2 JP 5593342B2
- Authority
- JP
- Japan
- Prior art keywords
- docetaxel
- deacetyl
- acid
- iii
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 29
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000002994 raw material Substances 0.000 claims description 22
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 12
- -1 2,4-dimethoxyphenyl Chemical group 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000012074 organic phase Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- FBQFZZDCDBAWNB-ZVTBYLAHSA-N (4s,5r)-2-(2,4-dimethoxyphenyl)-3-(2-nitrophenyl)sulfanyl-4-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound COC1=CC(OC)=CC=C1C1N(SC=2C(=CC=CC=2)[N+]([O-])=O)[C@@H](C=2C=CC=CC=2)[C@H](C(O)=O)O1 FBQFZZDCDBAWNB-ZVTBYLAHSA-N 0.000 claims description 5
- 238000011097 chromatography purification Methods 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- GJKJKILJCRTFNU-VEDVMXKPSA-N (5R)-2-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)[C@H]1CNC(O1)c1ccccc1 GJKJKILJCRTFNU-VEDVMXKPSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 7
- 229940123237 Taxane Drugs 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZDZOTLJHXYCWBA-MQOKZWAMSA-N 7-epidocetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-MQOKZWAMSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical class OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- KNWCDYSKJSREAQ-UHFFFAOYSA-N 1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)C1NCCO1 KNWCDYSKJSREAQ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229930190007 Baccatin Natural products 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000005103 alkyl silyl group Chemical group 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OVMSOCFBDVBLFW-VHLOTGQHSA-N (-)-Baccatin III Natural products O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 1
- KNWCDYSKJSREAQ-GSVOUGTGSA-N (2r)-1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1NCCO1 KNWCDYSKJSREAQ-GSVOUGTGSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical group OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- GJKJKILJCRTFNU-BDAKNGLRSA-N C1(=CC=CC=C1)[C@@H]1O[C@H](CN1)C(=O)O Chemical compound C1(=CC=CC=C1)[C@@H]1O[C@H](CN1)C(=O)O GJKJKILJCRTFNU-BDAKNGLRSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229930014667 baccatin III Natural products 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- QCOGLDHTESFSPY-BFLUDPMCSA-N chembl2096757 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](N)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 QCOGLDHTESFSPY-BFLUDPMCSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
b)該10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII(VI)と2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸(V)(以下、「オキサゾリジン酸(V)」と略すことがある)を反応させて、2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸,10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII 13−イル−エステル(VII)(以下、「エステル(VII)」と略すことがある)を得る工程、
上記工程e)が、10−デアセチル−N−デベンゾイルパクリタキセル(I)を二炭酸ジ−tert−ブチルと反応させること、及び、
得られるドセタキセルが、クロマトグラフによる精製なしに、99%超の純度を有し、対応する7−エピ体及び10−デヒドロ体の含量がそれぞれ0.1%未満であること
を特徴とするドセタキセルの製造方法
に関する。
10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII(VI)(中間原料(VI))
ピリジン60ml中において、撹拌しながら10−デアセチルバッカチンIII(15g)を塩化トリクロロアセチル6.6mlで0〜5℃で1時間処理する。この混合物を塩化メチレン100ml及び4N塩酸100mlで希釈する。相分離し、有機相を4N塩酸100ml及び飽和塩化ナトリウム水50mlで洗浄する。真空下で有機相を濃縮し、残渣をトルエン100mlに取る。濾過によって生成物(VI)を集め、真空下に50℃で乾燥する。この生成物(IV)をCH2Cl2(80ml)中に35℃で溶解させ、キーゼゲル 60 メルク(Kiesegel 60 Merck)800gを使用してカラムクロマトグラフィーによって精製する(溶出剤:CH2Cl2)。画分を合わせ(TLC:CH2Cl2)、HPLCによってチェックする。7−及び10−モノトリクロロアセチルバッカチンIIIの合計含有量は0.1%未満でなければならない。精製された化合物(VI)をトルエン中で沈殿させ、標記の化合物(17.8g、21.4mmol、660/26/B、A%純度:99%、収率:78%)を得る。
2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸,10−デアセチル−7,10−ビス−トリクロロアセチルバッカチンIII 13−イル−エステル(VII)(エステル(VII))
水100ml中にオキサゾリジン酸(V)10.3gをナトリウム塩の形で含む溶液を0〜5℃に冷却し、2M重硫酸ナトリウム溶液でpH2〜3に調整する。この反応混合物を0℃で15分間撹拌し、次いでCH2Cl2(70ml)を加える。2つの相に分離し、水相をCH2Cl2(1×50ml)で一度抽出する。合わせた有機相を飽和NaCl水溶液(1×25ml)(360g/l)で洗滌し、無水MgSO4(3g、KF0.12%)上で乾燥する。濾過後に溶液を室温で真空下に100mLまで濃縮する。黄色溶液に中間原料(VI)12gを加え、続いてジメチルアミノピリジン(DMAP)0.175g(1.42mmol)を加え、試薬の完全な溶解後にジシクロヘキシルカルボジイミド(DCC)5.88gを加える。この反応混合物を室温で1時間撹拌する。出発物質の中間原料(VI)がないことをTLC(酢酸エチル/ヘキサン:1/2、水(500mL)中にH2SO4(31ml)、モリブデン酸アンモニウム(19g)及び(NH4)4Ce(SO4)4・2H2O(1.9g)を含む溶液で噴霧し、130℃で5分間加熱することによって検出)によって検出する。形成したジシクロヘキシルウレア(DCU)の沈殿を濾別し、CH2Cl2(1×20mL)で洗浄する。この塩化メチレン溶液を蒸発乾固してエステル(VII)24gを得る。
2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸,10−デアセチルバッカチンIII 13−イル−エステル(VIII)(エステル(VIII))
テトラヒドロフラン100ml中エステル(VII)24gを含む溶液を真空下で濃縮し、その残渣をテトラヒドロフラン(THF)150mlで取り上げ、その混合物を真空下で100mlまで濃縮する。
10−デアセチル−N−デベンゾイルパクリタキセル(I)(中間原料(I))
メタノール260ml中のエステル(VIII)13gの懸濁液を室温で撹拌しながらメタノール130mlで希釈された濃塩酸水溶液4.2mlで30分間処理する。この反応混合物を室温で4時間撹拌すると懸濁液は透明な黄色の溶液になる。この混合物のTLCは、エステル(VIII)がまったく存在しないことを示す(酢酸エチル/ヘキサン:4/3)。この溶液を水(350ml)でゆっくりと(沈殿の形成を避けるために)希釈し、均一な溶液を室温で30分間撹拌する。CH2Cl2(200ml)を加え、2つの相に分離し、水相をCH2Cl2(2×100ml)で再び抽出する。有機相を除く。水性のアルコール相を0〜5℃に冷却し、CH2Cl2(1×100ml)で希釈する。激しい撹拌下に0〜5℃の濃アンモニア(3.1ml、NH4OH)を滴下しながらpH=7〜8まで加える(温度が1度上昇する)。2相反応を同じ温度で20分間撹拌し、次いで相を分離し、水相をCH2Cl2(5×100ml)で抽出する。
ドセタキセルの製造
中間原料(I)(16g、HPLC純度分析:90.57%、20.49mmol)を無水EtOHとCH2Cl2の1:1混合溶媒(320ml)中に溶解させ、わずかに黄色の溶液に、CH2Cl2中の二炭酸ジ−tert−ブチル(BOC)2O(24.18mmol、5.27gがCH2Cl25mlに溶解されている)を加える。添加の終りに、反応混合物を室温で16時間撹拌する。TLCは、中間原料(I)がまったく存在しないことを示す(CH2Cl2/MeOH:9/1、水(500ml)中にH2SO4(31ml)、モリブデン酸アンモニウム(19g)及び(NH4)4Ce(SO4)4・2H2O(1.9g)を含む溶液で噴霧し、130℃で5分間加熱することによって検出)。CH2Cl2を留去し、この溶液に酢酸(0.39ml)を加える。酸性のエタノール溶液を50℃に加熱し、純水(320ml)を滴下して加える。この混合物を50℃で1時間置き、室温でさらに2時間置く。焼結ガラスフィルターを通して沈殿物を濾過し、真空乾燥器内に移して、真空下に40℃で一晩中保持して、半精製されたドセタキセル16.75g及び捨てられうる母液1gを得る。
ドセタキセルの他の製造
1リットル反応器中にDe−BOCドセタキセル(30.0g、42mmol、HPLC純度98%、7−エピ異性体0.2%)を仕込み、次いで塩化メチレン60ml、無水アルコール150ml及び氷酢酸73μl(3%モル)を25℃で加え、懸濁液を得る。
Claims (3)
- 以下の工程を含むドセタキセルの製造方法であって:
a)10−デアセチルバッカチンIIIをピリジン中トリクロロアセチルクロライドと処理し、次いでメチレンクロライド/塩酸で得られた混合物を希釈し、分離した有機相を塩酸および飽和食塩水で洗浄し、最後に得られた製造物をカラムクロマトグラフで精製して10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII(VI)を得る工程;
b)10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII(VI)と2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸(V)を反応させて、2−(2,4−ジメトキシフェニル)−3−(2−ニトロベンゼンスルフェニル)−4(S)−フェニル−5(R)−オキサゾリジンカルボン酸,10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII 13−イル−エステル(VII)を得る工程;
上記工程b)の10−デアセチル−7,10−ビストリクロロアセチルバッカチンIII(VI)が、HPLCで定量して対応する7−及び10−モノトリクロロアセチル体の含量がそれぞれ0.1%未満であること、
上記工程e)が、10−デアセチル−N−デベンゾイルパクリタキセル(I)を二炭酸ジ−tert−ブチルと反応させること、及び、
得られるドセタキセルが、クロマトグラフによる精製なしに、99%超の純度を有し、対応する7−エピ体及び10−デヒドロ体の含量がそれぞれ0.1%未満であること
を特徴とするドセタキセルの製造方法。 - 前記工程e)の反応が、アルコール、塩素化炭化水素又はこれらの混合物から選ばれる溶媒中で、塩基の不存在下に、実施される請求項1に記載のドセタキセルの製造方法。
- 前記ドセタキセルが、エタノール/水混合物及び/又はアセトン/炭化水素混合物からの結晶化により精製される請求項1又は2に記載のドセタキセルの製造方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61684004P | 2004-10-08 | 2004-10-08 | |
EP04425752.5 | 2004-10-08 | ||
EP04425752A EP1647552A1 (en) | 2004-10-08 | 2004-10-08 | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
US60/616,840 | 2004-10-08 | ||
EP05007888A EP1712552A1 (en) | 2005-04-11 | 2005-04-11 | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
EP05007888.0 | 2005-04-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007535103A Division JP4971169B2 (ja) | 2004-10-08 | 2005-10-07 | 10−デアセチル−n−デベンゾイルパクリタキセルの製造のための半合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012136544A JP2012136544A (ja) | 2012-07-19 |
JP5593342B2 true JP5593342B2 (ja) | 2014-09-24 |
Family
ID=35445727
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007535103A Active JP4971169B2 (ja) | 2004-10-08 | 2005-10-07 | 10−デアセチル−n−デベンゾイルパクリタキセルの製造のための半合成方法 |
JP2012045438A Active JP5593342B2 (ja) | 2004-10-08 | 2012-03-01 | ドセタキセルの製造方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007535103A Active JP4971169B2 (ja) | 2004-10-08 | 2005-10-07 | 10−デアセチル−n−デベンゾイルパクリタキセルの製造のための半合成方法 |
Country Status (21)
Country | Link |
---|---|
US (3) | US7446126B2 (ja) |
EP (2) | EP2161260B1 (ja) |
JP (2) | JP4971169B2 (ja) |
KR (2) | KR101216885B1 (ja) |
CN (2) | CN100584836C (ja) |
AT (1) | ATE451360T1 (ja) |
AU (2) | AU2005291357B2 (ja) |
CA (2) | CA2582545C (ja) |
DE (1) | DE602005018238D1 (ja) |
DK (2) | DK2161260T3 (ja) |
ES (2) | ES2531393T3 (ja) |
HK (2) | HK1108317A1 (ja) |
IL (2) | IL182396A (ja) |
MX (1) | MX2007004157A (ja) |
NO (2) | NO339631B1 (ja) |
NZ (2) | NZ585629A (ja) |
PL (2) | PL1797059T3 (ja) |
PT (2) | PT2161260E (ja) |
RU (2) | RU2384578C2 (ja) |
SI (2) | SI1797059T1 (ja) |
WO (1) | WO2006037653A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
ITMI20050614A1 (it) * | 2005-04-12 | 2006-10-13 | Indena Spa | Processo per la purificazione della 10-deacetilbaccatina iii dalla 10-deacetil-2-debenzoil-2-pentenoilbaccatina iii |
AU2007226937A1 (en) * | 2006-03-21 | 2007-09-27 | Dr. Reddy's Laboratories Ltd. | Docetaxel polymorphs and processes |
PL210984B1 (pl) * | 2006-10-31 | 2012-03-30 | Inst Farmaceutyczny | Sposób wytwarzania docetakselu |
PL388144A1 (pl) | 2009-05-29 | 2010-12-06 | Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością | Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie |
KR101149600B1 (ko) * | 2009-12-31 | 2012-05-29 | 주식회사 삼양제넥스바이오 | 고순도 무수결정형 도세탁셀 제조방법 |
CA2798180A1 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US10287918B2 (en) | 2013-02-19 | 2019-05-14 | United Technologies Corporation | Composite attachment structure with 3D weave |
CN108822062B (zh) * | 2018-09-07 | 2020-08-28 | 无锡紫杉药业有限公司 | 一种多西他赛的精制方法 |
WO2020249507A1 (en) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
KR20230069345A (ko) | 2021-11-12 | 2023-05-19 | 닥터아이앤비(주) | 생산 시간을 단축하고 안정성이 개선된 의약품 제조방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9102128A (es) * | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
FR2696458B1 (fr) * | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
FR2718963B1 (fr) * | 1994-04-25 | 1996-05-24 | Rhone Poulenc Rorer Sa | Nouvelle composition pharmaceutique à base de taxoïdes. |
CA2170661A1 (en) * | 1995-03-22 | 1996-09-23 | John K. Thottathil | Novel methods for the preparation of taxanes using oaxzolidine intermediates |
IT1308636B1 (it) * | 1999-03-02 | 2002-01-09 | Indena Spa | Procedimento per la preparazione di tassani da 10-desacetilbaccatinaiii. |
IT1318678B1 (it) * | 2000-08-10 | 2003-08-27 | Indena Spa | Procedimento per la preparazione di derivati della baccatina iii. |
IT1320107B1 (it) * | 2000-11-28 | 2003-11-18 | Indena Spa | Procedimento per la preparazione di derivati tassanici. |
US6881852B2 (en) * | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
ITMI20020782A1 (it) | 2002-04-12 | 2003-10-13 | Indena Spa | Processo semisintetico per la preparazione di n-debenzoilpaclitaxel |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
-
2005
- 2005-10-06 US US11/244,171 patent/US7446126B2/en active Active
- 2005-10-07 SI SI200530893T patent/SI1797059T1/sl unknown
- 2005-10-07 US US11/664,782 patent/US20080167369A1/en not_active Abandoned
- 2005-10-07 CA CA2582545A patent/CA2582545C/en active Active
- 2005-10-07 CN CN200580033957A patent/CN100584836C/zh active Active
- 2005-10-07 KR KR1020097007134A patent/KR101216885B1/ko active IP Right Grant
- 2005-10-07 SI SI200531961T patent/SI2161260T1/sl unknown
- 2005-10-07 NZ NZ585629A patent/NZ585629A/en unknown
- 2005-10-07 RU RU2007112775/04A patent/RU2384578C2/ru active
- 2005-10-07 WO PCT/EP2005/010822 patent/WO2006037653A1/en active Application Filing
- 2005-10-07 PL PL05798522T patent/PL1797059T3/pl unknown
- 2005-10-07 RU RU2009143794/04A patent/RU2510395C2/ru active
- 2005-10-07 EP EP09175976.1A patent/EP2161260B1/en active Active
- 2005-10-07 ES ES09175976T patent/ES2531393T3/es active Active
- 2005-10-07 AU AU2005291357A patent/AU2005291357B2/en active Active
- 2005-10-07 PL PL09175976T patent/PL2161260T3/pl unknown
- 2005-10-07 KR KR1020077007382A patent/KR101146839B1/ko active IP Right Grant
- 2005-10-07 DE DE602005018238T patent/DE602005018238D1/de active Active
- 2005-10-07 CA CA2791783A patent/CA2791783C/en active Active
- 2005-10-07 EP EP05798522A patent/EP1797059B1/en active Active
- 2005-10-07 MX MX2007004157A patent/MX2007004157A/es active IP Right Grant
- 2005-10-07 DK DK09175976T patent/DK2161260T3/da active
- 2005-10-07 PT PT09175976T patent/PT2161260E/pt unknown
- 2005-10-07 AT AT05798522T patent/ATE451360T1/de active
- 2005-10-07 PT PT05798522T patent/PT1797059E/pt unknown
- 2005-10-07 ES ES05798522T patent/ES2333738T3/es active Active
- 2005-10-07 DK DK05798522.8T patent/DK1797059T3/da active
- 2005-10-07 JP JP2007535103A patent/JP4971169B2/ja active Active
- 2005-10-07 NZ NZ554344A patent/NZ554344A/en unknown
- 2005-10-07 CN CN200910220891.0A patent/CN101704804B/zh active Active
-
2007
- 2007-04-10 IL IL182396A patent/IL182396A/en active IP Right Grant
- 2007-04-10 NO NO20071835A patent/NO339631B1/no unknown
- 2007-12-13 HK HK07113620.4A patent/HK1108317A1/xx unknown
-
2008
- 2008-04-17 US US12/104,715 patent/US8318957B2/en active Active
-
2010
- 2010-07-19 HK HK10106972.7A patent/HK1140490A1/xx unknown
- 2010-09-21 IL IL208290A patent/IL208290A/en active IP Right Grant
-
2011
- 2011-03-29 AU AU2011201419A patent/AU2011201419B2/en active Active
-
2012
- 2012-03-01 JP JP2012045438A patent/JP5593342B2/ja active Active
-
2016
- 2016-07-11 NO NO20161147A patent/NO340930B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5593342B2 (ja) | ドセタキセルの製造方法 | |
JP2015057423A (ja) | 無水ドセタキセルの製造方法 | |
JP2002538155A (ja) | 10−デアセチルバカチンiiiからタキサンを調製する方法 | |
KR100847331B1 (ko) | 도세탁셀의 제조방법 및 이에 사용되는 중간체 | |
JP2010513472A (ja) | タキサン誘導体の製造方法及びそれに用いられる中間体 | |
KR101032761B1 (ko) | 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체 | |
JP5870197B2 (ja) | タキサン誘導体の製造方法 | |
KR101003820B1 (ko) | 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체 | |
EP1712552A1 (en) | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel | |
EP1647552A1 (en) | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140210 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140530 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20140602 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140602 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140708 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140804 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5593342 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |